Life sciences companies began the year 2020 with significant challenges, including COVID-19. The virus created an instant demand to fast-track products without sacrificing quality and profitability and to ensure continuity of medical supplies. Add to that challenge the increasing pressure on life sciences companies from generics. Development and manufacturing costs were increasing, along with customer expectations. And there were regulatory changes.
The Everest Group evaluated all of these processes using a proprietary methodology to assess the suitability of processes for automation. Named the “Enterprise Value Chain Approach” (EVCA), this five-step methodology helps businesses identify business processes, analyze each process, spotlight high-value opportunities for automation, and define metrics to prioritize those opportunities.
